Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

260.10GBp
21 Sep 2018
Change (% chg)

-5.50 (-2.07%)
Prev Close
265.60
Open
267.70
Day's High
268.50
Day's Low
257.40
Volume
3,168,703
Avg. Vol
3,093,191
52-wk High
504.60
52-wk Low
238.00

Latest Key Developments (Source: Significant Developments)

Standard Life Aberdeen Affiliates Raises Stake To 10.03 Pct In Indivior
Thursday, 20 Sep 2018 10:50am EDT 

Sept 20 (Reuters) - Indivior PLC ::STANDARD LIFE ABERDEEN AFFILIATES RAISES STAKE TO 10.03 PERCENT FROM 7.09 PERCENT IN INDIVIOR PLC - FILING.  Full Article

Indivior Says ‍U.S. Court Found Alvogen Does Not Infringe Claims Of Certain U.S. Patent​s
Friday, 23 Mar 2018 03:01am EDT 

March 23 (Reuters) - Indivior Plc ::INDIVIOR RESPONDS TO COURT RULING ANDA LITIGATION.‍RESPONDS TO COURT RULING IN ANDA LITIGATION AND ANNOUNCES INTENTION TO APPEAL.INDIVIOR - ‍US DISTRICT COURT FOR DISTRICT OF DELAWARE HAS FOUND THAT ALVOGEN DOES NOT INFRINGE ASSERTED CLAIMS OF CERTAIN U.S. PATENT​S.INDIVIOR PLC <<>> - ‍BELIEVES THAT IT HAS GROUNDS TO APPEAL RULING BY DISTRICT COURT OF DELAWARE​.INDIVIOR - WILL NOT BE ABLE TO RELY ON '514, '150, AND '497 PATENTS TO PREVENT ALVOGEN FROM MANUFACTURING AND MARKETING A GENERIC FILM ALTERNATIVE IN US​​.‍FINANCIAL GUIDANCE FOR FY 2018, PROVIDED BY INDIVIOR ON FEBRUARY 15, 2018, IN ITS FY 2017 RESULTS, ASSUMED NO GENERIC FILM LAUNCH IN 2018​.‍COMPANY WILL CONTINUE TO MONITOR MARKET CONDITIONS AND WILL UPDATE ITS FINANCIAL GUIDANCE IF APPROPRIATE..INDIVIOR - WILL NOT BE ABLE TO RELY ON '514, '150, AND '497 PATENTS TO PREVENT ALVOGEN FROM MANUFACTURING AND MARKETING A GENERIC FILM ALTERNATIVE IN US​.INDIVIOR PLC <<>> - ‍IF FDA GRANTS APPROVAL TO ALVOGEN, IT WOULD BE ABLE TO MARKET A GENERIC ALTERNATIVE TO SUBOXONE® FILM IN US​.INDIVIOR - ‍EXPECT TO EXTEND MARKET LEADING POSITION IN ADDICTION DISEASE SPACE, REMAIN CONFIDENT IN ACHIEVING AT LEAST $1 BLN IN PEAK SUBLOCADE NET REVENUE​​.  Full Article

Indivior Says FY 2017 ‍Net Revenue Increased 3% On Reported Basis
Thursday, 15 Feb 2018 02:00am EST 

Feb 15 (Reuters) - Indivior Plc ::FY 2017 ‍NET REVENUE AT $1,093M (FY 2016: $1,058M) INCREASED 3% ON A REPORTED BASIS (3% AT CONSTANT EXCHANGE)​.FY 2017 ‍NET INCOME WAS $58M (FY 2016: $35M)​.FY 2017 ‍CASH BALANCE AT PERIOD END WAS $863M (FY 2016: $692M). NET CASH WAS $376M (FY 2016: $131M)​.  Full Article

Indivior Expects High Teens Effective Tax Rate For 2018​
Thursday, 1 Feb 2018 02:00am EST 

Feb 1 (Reuters) - Indivior Plc ::INDIVIOR PROVIDES UPDATE ON TAX POSITION.‍EXPECTS ITS FUTURE US AFTER-TAX INCOME TO BE POSITIVELY IMPACTED BY RECENTLY-LEGISLATED CHANGES TO US CORPORATE TAXES​.‍EXPECTS A HIGH TEENS EFFECTIVE TAX RATE FOR 2018​.‍ESTIMATED IMPACT OF THIS WILL BE A ONE-OFF NON-CASH CHARGE TO COMPANY'S AFTER-TAX INCOME OF APPROXIMATELY $15 MILLION THAT WILL IMPACT Q4.  Full Article

Addex and Indivior Sign Strategic Partnership
Wednesday, 3 Jan 2018 01:00am EST 

Jan 3 (Reuters) - ADDEX THERAPEUTICS LTD ::REG-ADDEX AND INDIVIOR SIGN STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF GABAB PAMS AS ADDICTION TREATMENTS.UNDER TERMS OF AGREEMENT, ADDEX WILL RECEIVE $5 MILLION UPFRONT.UNDER TERMS OF AGREEMENT WILL RECEIVE $4 MILLION OF COMMITTED RESEARCH FUNDING OVER NEXT TWO YEARS.TO RECEIVE $330 MILLION OF POTENTIAL DEVELOPMENT.WILL RECEIVE REGULATORY AND COMMERCIALIZATION MILESTONES AND TIERED ROYALTIES UP TO DOUBLE-DIGIT.  Full Article

‍Indivior Says Repricing And Maturity Extension Of Term Loan Facilities
Tuesday, 19 Dec 2017 02:00am EST 

Dec 19 (Reuters) - INDIVIOR PLC ::‍INDIVIOR ANNOUNCES REPRICING AND MATURITY EXTENSION OF TERM LOAN FACILITIES AND REPLACEMENT OF CREDIT FACILITY​.‍ENTERED AMENDMENT WITH VARIOUS LENDERS TO PROVIDE REPLACEMENT TERM LOAN FACILITIES IN AN AGGREGATE PRINCIPAL AMOUNT OF APPROXIMATELY $484 MILLION​.‍NEW TERM LOAN FACILITIES REDUCE GROUP'S INTEREST COUPON TO LIBOR PLUS 4.50% FROM LIBOR PLUS 6.00 PERCENT​.  Full Article

Indivior Announces NDA Acceptance Of RBP-7000 Risperidone Monthly Depot
Tuesday, 12 Dec 2017 07:00am EST 

Dec 12 (Reuters) - Indivior Plc ::INDIVIOR ANNOUNCES NDA ACCEPTANCE OF RBP-7000 RISPERIDONE MONTHLY DEPOT.FDA HAS SET A PDUFA TARGET ACTION DATE OF JULY 28, 2018.  Full Article

Indivior says Q3 net revenue $‍275​ mln vs. $268 mln
Thursday, 2 Nov 2017 07:00am EDT 

Nov 2 (Reuters) - Indivior Plc ::Q3 NET REVENUE $‍275​ MILLION VERSUS $268 MILLION A YEAR AGO.FY 2017 REVENUE AND NET INCOME GUIDANCE RECONFIRMED​.Q3 NET PROFIT $‍50 MILLION VERSUS LOSS OF $149 MILLION A YEAR AGO.SUBOXONE FILM MARKET SHARE AVERAGED 58 PCT IN YTD 2017 (YTD 2016: 61%).‍FINALIZING LAUNCH PLANS OF RBP-6000, WORKING WITH 3RD-PARTY MANUFACTURING PARTNERS TO APPROPRIATE DELIVERY TO ENABLE TARGET LAUNCH IN Q1 2018​.  Full Article

FDA committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder
Tuesday, 31 Oct 2017 04:58pm EDT 

Oct 31 (Reuters) - Indivior PLC :FDA advisory committees recommend approval of Indivior's RBP-6000 for the treatment of opioid use disorder.Indivior PLC - ‍FDA has set a prescription drug user fee act (PDUFA) target action date of November 30, 2017​.  Full Article

Old Mutual cuts stake in Indivior to 4.36 pct
Monday, 9 Oct 2017 08:00am EDT 

Oct 9 (Reuters) - Indivior Plc :OLD MUTUAL CUTS STAKE IN INDIVIOR TO 4.36 PERCENT FROM 7.01 PERCENT STAKE EARLIER- FILING‍​.  Full Article

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.